Source : NewMediaWire

Pivot Pharmaceuticals Up-Lists to OTCQB(R) Venture Marketplace

BOSTON, MA and VANCOUVER, BC--(Marketwired - Oct 5, 2015) - Pivot Pharmaceuticals Inc. (OTCQB: PVOTF) ("Pivot" or the "Company"), an emerging biotechnology company engaged in the development of therapeutics to meet unmet medical needs in women's health, is pleased to announce that the Company's stock has been up-listed to the OTCQB® Venture Marketplace. Shares shall commence trading under the symbol "PVOTF" effective today.

The OTCQB® Venture Marketplace offers investors transparent trading in entrepreneurial and development stage U.S. and international companies. Beginning on March 26, 2014, OTCQB® companies were required to meet more stringent standards and eligibility requirements. To be eligible for OTCQB®, companies must meet a minimum of bid price test, be current in their reporting and undergo a new annual verification and management certification process designed to improve the information available to investors. OTCQB® companies must be registered and current in their reporting with the SEC or a U.S. regulatory agency.

BJ Bormann, Chief Executive Officer of Pivot Pharmaceuticals stated, "Becoming an OTCQB® listed company marks an important achievement for Pivot Pharmaceuticals and reveals the hard work and dedication of our entire team. We are proud of the Company we have become and believe that trading on OTCQB® will enhance trading liquidity."

Trading on the OTCQB® allows investors easier access to Pivot's shares, real time quotes, as well as access to financial disclosures and reports on the Company's stock activity at

About Pivot Pharmaceuticals Inc.
Pivot is an early stage biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceutical products, with a strategic emphasis on the innovation of new therapeutic uses for existing drugs to treat unmet conditions related to women's health. Pivot has identified ideal candidates for the treatment of Dysmenorrhea, lower urinary tract symptoms (LUTS), and menopausal symptoms (hot flushes).

About OTC Markets Group Inc.

OTC Markets Group Inc. (OTCQX: OTCM) operates Open, Transparent and Connected financial markets for 10,000 U.S. and global securities. Through our OTC Link® ATS, we directly link a diverse network of broker-dealers that provide liquidity and execution services for a wide spectrum of securities. We organize these securities into markets to inform investors of opportunities and risks: the OTCQX® Best Market; the OTCQB® Venture Market; and the OTC Pink® Open Market. Our data-driven platform enables investors to easily trade through the broker of their choice at the best possible price and empowers a broad range of companies to improve the quality and availability of information for their investors. To learn more about how we create better informed and more efficient financial markets, visit

OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and SEC regulated ATS.

Cautionary Statement
Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as anticipate, believe, estimate, expect, intend, and similar expressions, as they relate to Pivot Pharmaceuticals or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, such as the level of business and consumer spending, the amount of sales of Pivot's products, the competitive environment within the industry, the ability of Pivot to continue to expand its operations, the level of costs incurred in connection with Pivot's expansion efforts, economic conditions in the industry, and the financial strength of Pivot's customers and suppliers. Pivot does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.

Contact Information:


Pivot Pharmaceuticals Inc.
BJ Bormann
Chief Executive Officer
Tel: (860) 333-3700

PCG Advisory Group
Sean Leous
Chief Communications Officer
(646) 863-8998